Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
unconjugated meningococcal polysaccharide vaccine (serogroups A, C)
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
**Unconjugated meningococcal polysaccharide vaccine (serogroups A, C)** is a bacterial vaccine composed of purified capsular polysaccharides derived from *Neisseria meningitidis* serogroups A and C. Unlike conjugate vaccines, these polysaccharides are not linked to a protein carrier. The vaccine works by inducing an immune response against the capsular polysaccharides, generating serum bactericidal antibodies that protect against invasive meningococcal disease caused by serogroups A and C. It is formulated as a lyophilized powder and typically administered via intramuscular or subcutaneous injection. The unconjugated form is primarily used for outbreak control in specific regions and age groups, and is less commonly used than conjugate vaccines due to limited immune memory and effectiveness in young children[7].
- Brand names
- NmVac4-A/CMencevax AC
- Other names
- unconjugated meningococcal polysaccharide vaccine (serogroups A, C)
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on unconjugated meningococcal polysaccharide vaccine (serogroups A, C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on unconjugated meningococcal polysaccharide vaccine (serogroups A, C).